Weight Management

FDA clears oral Wegovy pills for weight loss, while Lemme Burn Gummies tout metabolic support; plus new thalassemia anemia drug and Lucentis biosimilar.

A multicohort analysis reveals that obesity substantially increases hospitalization and mortality risk across diverse infectious diseases.

WADA tracks GLP-1s like Ozempic, Wegovy, and Zepbound at the Olympics as pharmacists weigh muscle-loss risks and sports pharmacy guidance.

The FDA targets mass-marketed compounded GLP-1 drugs, warning of safety risks and deceptive ads as enforcement ramps up for weight-loss injectables.

Learn how pharmacists cut GLP-1 costs, streamline prior authorizations, guide safe switches, and bust social media myths for lasting adherence.

Pharmacists are critical in supporting GLP-1 therapy success through proactive expectation setting.

The scientific statement underscores obesity as a complex, socially driven condition and positions pharmacists as key partners in reducing stigma, improving access to care, and supporting equitable weight management.

Pharmacists play a vital role in countering GLP-1 misinformation.

Treatment with semaglutide offers benefits beyond solely cardiovascular risk reduction, lowering the risk of hospitalization across a range of comorbidities.

Pharmacists play a critical role in improving access to and affordability of GLP-1 therapies.

Research data show that weight regain after discontinuation of GLP-1 or GLP-1/GIP agonists is a significant risk.

David Shusterman, MD, reveals how reducing alcohol enhances GLP-1 therapy, improving insulin regulation, kidney health, and overall metabolic outcomes.

GLP-1 receptor agonist effectiveness and tolerability can be significantly improved through targeted pharmacist counseling on alcohol reduction.

The American Heart Association (AHA) has released new guidance highlighting numerous obstacles that individuals with obesity face when treating and managing their condition, including limited access to healthy foods and weight stigma.

The FDA approved oral semaglutide to reduce the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D).

The glucagon-like peptide-1 (GLP-1) receptor agonist medications evaluated included semaglutide, tirzepatide, and liraglutide.

A tour through GLP-1’s unexpected biology.

Explore the differences between oral and injectable semaglutide for weight management, focusing on adherence, adverse effects, and patient preferences.

The pivotal clinical trial supports the concomitant administration of tirzepatide and ixekizumab, which significantly improves outcomes for patients with psoriatic arthritis (PsA) and obesity.

Recent studies reveal that weight recovery in anorexia nervosa does not ensure muscle restoration, highlighting the need for comprehensive recovery strategies.

New oral GLP-1 agonist orforglipron cuts A1C and drives meaningful weight loss in trials, offering easier dosing than injections.

GoodRx enhances access to semaglutide with affordable cash pricing, revolutionizing obesity treatment and supporting patients in weight management.

Orforglipron shows promise in maintaining weight loss for individuals transitioning from injectable therapies, offering a convenient oral option for obesity management.

The FDA approved the first oral GLP-1 pill for weight management, offering a convenient alternative for obesity treatment and enhancing patient access.

Retatrutide shows promising results in reducing weight and knee pain for individuals with obesity and osteoarthritis, enhancing physical function significantly.